Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints ...

FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 ...

Limited (“ HUTCHMED ”) (Nasdaq/AIM:?HCM; HKEX:?13) today announces that it has initiated the Phase III part of the Phase II/III trial to evaluate the efficacy of the combination of surufatinib, ...

Discover Claude’s Ask User Question, which asks targeted prompts about endpoints, interfaces, and structure, so you craft stronger specs faster ...

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically ...

Transparent Tribe (APT36) is linked to new cyber-espionage attacks using malicious LNK files, adaptive RATs, and long-term ...

Dupilumab, a fully human monoclonal antibody, inhibits the signaling of the interleukin 4 (IL-4) and IL-13 pathways.

David Mytton, founder and CEO of Arcjet, leads the developer-focused security startup that helps teams embed robust protections like bot detection, rate limiting, email validation, attack mitigation, ...

One such event occurred in December 2024, making it worthy of a ranking for 2025. The hackers behind the campaign pocketed as ...

US FDA accepts Axsome Therapeutics’ supplemental New Drug Application for AXS-05 to treat Alzheimer’s disease agitation: New York Saturday, January 3, 2026, 12:00 Hrs [IST] Ax ...